ACRI- Phase 1
Anaheim, California, 92801, United States
NCT Number: NCT01324752
The purpose of this study is to determine if Losartan potassium is affected by PA21.
Looking for future studies?
Notify Me20 year–50 year
All sexes
Interventional
Phase 1
Anaheim, California, 92801, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
The maximum dose of Losartan will be 100 mg/day.
The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
Time frame: PK assessment on Day 0, 11, 22
To assess the effect, if any, of PA21 on Losartan potassium exposure
Time frame: PK assessment on Day 0, 11, 22
To assess the effect, if any, of PA21 on the active metabolite of Losartan potassium
Vifor Pharma
Industry
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05558150
Drug Interaction Potentiation
Seoul, South Korea
View Trial DetailsNCT05237297
Drug Interaction Potentiation
Seoul, South Korea
View Trial DetailsNCT03123640
Behavior, Chemically-Induced Disorders
Oslo, Norway
View Trial DetailsNCT03493698
Drug Interaction Potentiation
Groningen, Netherlands
View Trial Details